Athersys, Inc. Receives Orphan Drug Designation for MultiStem in Hurler's Syndrome

Full story: BioSpace

Athersys, Inc. announced today that MultiStemA , Athersys' proprietary cell therapy, has been granted orphan drug designation by the U.S. Food and Drug Administration for the treatment of Hurler's Syndrome, also known as mucopolysaccharidosis type I or MPS-I. Hurler's Syndrome is a lysosomal storage disorder that affects approximately 1 of every ... (more)
Comments
1 - 2 of 2 Comments Last updated Jul 17, 2012
athxer

Singapore, Singapore

|
Report Abuse
|
Judge it!
|
#1
Jul 11, 2012
 
any idea when a partnership for this is happening??? Don;t wish to see another dilution exercise.
athxer

Singapore, Singapore

|
Report Abuse
|
Judge it!
|
#2
Jul 17, 2012
 
I'm starting to loose patience at Athersys. Whenever there's slightest bit of positive news, this damn stock will go down and remain down.

Tell me when this thread is updated: (Registration is not required)

Add to my Tracker Send me an email

Type in your comments below
Name
(appears on your post)
Comments
Characters left: 4000
Type the numbers you see in the image on the right:

Please note by clicking on "Post Comment" you acknowledge that you have read the Terms of Service and the comment you are posting is in compliance with such terms. Be polite. Inappropriate posts may be removed by the moderator. Send us your feedback.

•••
•••